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Background: To ascertain the trends in mortality from Asbestosis, Extrinsic Allergic Alveolitis
(EAA) and Sarcoidosis in England and Wales, we analysed mortality data from the Office of
National Statistics.
Methods: We calculated age and stratum specific mortality rates between 1968 and 2008 and
applied these to the 2008 population to generate annual standardised expected number of
deaths. Poisson regression was used to calculate annual mortality rate ratios.
Results: From 1968 to 2008 there were 1958 registered deaths from Asbestosis, 878 deaths
from EAA and 3544 deaths from Sarcoidosis. The Asbestosis mortality rate increased from
0.04 (95% CI 0.03e0.05) in the 1968e1972 calendar period to 0.12 (95% CI 0.10e0.13) in the
2005e2008 period whist the mortality from EAA increased marginally from 0.04 (95% CI 0.03
e0.05) in the 1968e1972 calendar period to 0.08 (95% CI 0.07e0.09) in the 2005e2008 period.
Mortality from Sarcoidosis increased by approximately 9% a year.
Discussion: Our findings show that the mortality from Asbestosis continues to rise in the UK.
Overall mortality rates from EAA remained stable throughout the same period but it was higher
in males and in older people. There was a slight increase in mortality from Sarcoidosis over the
study period which was greater in women.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Asbestosis, Extrinsic Allergic Alveolitis (EAA) and Sarcoid-
osis are three of the more common types of interstitial lung
disease that present to respiratory outpatient clinics, butRespiratory, Biomedical Resear
.
@nottingham.ac.uk (V. Navaratna
1 Elsevier Ltd. All rights reservedthere is limited information available on the mortality
trends for these conditions.
Using registered death certificates to examine the
mortality trends over time is an established method of
examining the burden of a disease, and has been usedch Unit, Nottingham City Hospital, Hucknall Road, Nottingham,
m).
.
1374 A. Hanley et al.previously in interstitial lung disease, more specifically,
cryptogenic fibrosing alveolitis and idiopathic pulmonary
fibrosis.1e3
The aim of this study is to investigate the mortality rates
of Asbestosis, Extrinsic Allergic Alveolitis and Sarcoidosis,
stratified by age and sex in England and Wales and to
determine if mortality from these three diseases had
changed over time.
Methods
Data collection
We used routine mortality data from the Office of National
Statistics (ONS), which is derived from registered death
certificates and coded for the underlying cause of deaths.Table 1 International Classification of Diseases codes used to ex
Disease ICD Codes
Asbestosis
ICD-8 515.2 Asbestosis
ICD-9 501 Asbestosis
ICD-10 J61 Pneumoconiosis
J92.0 Pleural plaque
Extrinsic Allergic Alveolitis
ICD-8 516.1 Other pneumo
ICD-9 495.0 Farmer’s lung
495.1 Bagassosis
495.2 Bird fancier’s
495.3 Suberosis
495.4 Maltworker’s l
495.5 Mushroom wo
495.6 Maple-Bark-St
495.7 ‘Ventilation’ p
495.8 Other specifie
495.9 Unspecified al
ICD-10 J67.0 Farmer’s lung
J67.1 Bagassosis
J67.2 Bird fancier’s
J67.3 Suberosis
J67.4 Maltworker’s l
J67.5 Mushroom wor
J67.6 Maple-Bark-St
J67.7 Air conditione
J67.8 Hypersensitivi
J67.9 Hypersensitivi
Sarcoidosis
ICD-8 135 Sarcoidosis
ICD-9 135 Sarcoidosis
517.8 Lung involvem
ICD-10 D86.0 Sarcoidosis of
D86.1 Sarcoidosis of
D86.2 Sarcoidosis of
D86.3 Sarcoidosis of
D86.8 Sarcoidosis of
D86.9 Sarcoidosis, uThis dataset is available on CD-ROM and can be obtained
electronically from the ONS’s website (www.ons.gov.uk).
Over this period of time, three different ICD codes were
used to code death from Asbestosis, Extrinsic Allergic
Alveolitis (EAA) and Sarcoidosis (see Table 1).
Data analysis
Annual number of deaths from Asbestosis, EAA and
Sarcoidosis were obtained for the years 1968e2008 strati-
fied be age and sex. We used the total population from
England and Wales for each disease for the years
1968e2008 as our denominators.
For these analyses, the data on registered deaths and the
general population were grouped in approximately 5 year
periods but without combining the different ICD codes. Data
for Asbestosis and EAAwas also grouped into 5 year age bandstract the mortality data from the Office of National Statistics.
due to asbestos and other mineral fibres
with presence of asbestos
coniosis and related diseases due to inhalation of other dust
lung
ung
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ripper’s lung
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Figure 1 Estimated number of deaths from Asbestosis, age
standardised to the 2008 population of England and Wales.
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into 5 year age bands over the age of 35 years. We calculated
age and sex stratum specific mortality rates for each year
and then applied these rates to the 2008 population to
generate annual standardised mortality numbers.
Poisson regression modelling was used to estimate
annual mortality rate ratios with adjustment for sex and
age. A multiplicative interaction term was used to test forTable 2 Standardised mortality rates and Poisson regression m
Ndths Personeyears
(million)
Morta
(stand
100 0
Calendar period
ICD-8 1968e1972 102 270 0.04 (
1973e1978 168 330 0.05 (
1979e1983 173 270 0.06 (
ICD-9 1984e1988 209 270 0.08 (
1989e1994 331 330 0.10 (
1995e2000 335 330 0.10 (
ICD-10 2001e2004 385 220 0.18 (
2005e2008 255 220 0.12 (
Sex
Male 1785 110 0.16 (
Female 173 110 0.02 (
Age group (years)
0e54 92 160 0.01 (
55e59 140 130 0.11 (
60e64 231 130 0.17 (
65e69 322 100 0.32 (
70e74 412 870 0.47 (
75e79 382 720 0.53 (
80e84 242 530 0.45 (
85 and above 137 490 0.28 (
All the mortality rate ratios are mutually adjusted for all other variainteractions between mortality rates in the different
calendar periods and age or sex.
Results
Asbestosis
There were 1958 deaths attributed to Asbestosis in England
andWales from 1968 to 2008. The number of recorded deaths
increased from 13 (11 after standardisation to the 2008 pop-
ulation) in 1968 to 129 (124 after standardisation) in 2006 (see
Fig. 1). There was a sharp decline in the number of deaths in
2007 (5deaths) and2008 (3 deaths)whichdoes notfitwith the
overall trend of deaths seen and is likely to be an error in
coding of death registrations. The overall mortality rate for
the study period was 0.09 per 100 000 person years (95% CI
0.08e0.09), with the mortality rate increasing from 0.04 per
100 000 person years (95% CI 0.03e0.05) in the 1968e1972
calendar period to 0.12 per 100 000 person years (95% CI
0.10e0.13) in the2005e2008 calendarperiod. After adjusting
for age and sex, the number of deaths from Asbestosis had
increased by three fold during the study period. Mortality
from Asbestosis was found to be higher in men compared to
women, and also higher with increasing age categories.
There was evidence of a statistical interaction to suggest
that the increase in mortality rates over time were higher in
the older population (p< 0.001) and in men (p< 0.001). The
age group specific mortality rate ratios were 0.76 (95% CI
0.69e0.85) for individuals aged 0e54, for 0.86 (95% CI 0.80 to
0.93) in individuals aged 55e59 years, 1.00 (95% CI
0.94e1.06) in individuals aged 60e64 years, 1.20 (95% CIodelling of deaths from Asbestosis.
lity rate
ardised to 2008 pop per
00 (95% confidence interval))
Mutually adjusted
rate ratios (95% confidence
intervals)
0.03e0.05) 1.00
0.04e0.06) 1.37 (1.07e1.76)
0.06e0.07) 1.70 (1.33e2.17)
0.07e0.09) 2.05 (1.62e2.60)
0.09e0.11) 2.70 (2.17e3.38)
0.09e0.11) 2.74 (2.19e3.42)
0.16e0.20) 4.72 (3.79e5.87)
0.10e0.13) 3.13 (2.48e3.93)
p for trend <0.001
0.16e0.17) 1.00
0.01e0.02) 0.08 (0.07e0.09)
p < 0.001
0.01e0.01) 0.02 (0.01e0.02)
0.09e0.13) 0.32 (0.27e0.39)
0.15e0.20) 0.53 (0.45e0.63)
0.29e0.36) 1.00
0.43e0.52) 1.50 (1.30e1.73)
0.48e0.59) 1.76 (1.52e2.04)
0.40e0.52) 1.64 (1.39e1.94)
0.23e0.33) 1.21 (0.99e1.47)
p for trend <0.001
bles in the table.
1376 A. Hanley et al.1.15e1.26) in those aged 70e74 years, for the 1.42 (95% CI
1.35e1.49) in individuals aged 75e79 years, 1.64 (95% CI
1.52e1.77) in individuals between 80 and 84 years and 1.80
(95% CI 1.61e2.00) who are 85 years or above. The mortality
rate ratios for men and women were 1.23 (95% CI 1.21e1.26)
and 0.90 (95% CI 0.84e0.97) respectively (Table 2).
Extrinsic Allergic Alveolitis
There were 878 deaths from EAA over the study period. The
mortality rate over time for EAA was stable throughout.
Mortality rates were higher in men at 0.05 per 100 000 (95%
CI 0.05e0.06) compared to women (see Table 3). Mortality
rates also increased with age until a peak in the 80e84 age
group with a rate of 0.19 per 100 000 (95% CI 0.15e0.23).
There was evidence of a statistical interaction to suggest
that the increase in mortality rates over time was higher in
the older population (p < 0.001) and in men (p Z 0.0078).
For individuals aged under 55 years, the age group specific
mortality rate ratio was 1.02 (95% CI 0.94e1.11), for indi-
viduals in the 60e64age group itwas 0.96 (95%CI 0.89e1.05),
and for those in the 65e69 age group the rate ratio was 1.01
(95% CI 0.93e1.08). For individuals between 70 and 74 years,
the rate ratio was 1.11 (95% CI 1.03e1.19). Individuals aged
75e79 years had a rate ratio of 1.23 (95% CI 1.13e1.33), in
those aged 80e84 years itwas 1.30 (95%CI 1.18e1.43) and for
individuals over 85 years it was 1.71 (95% CI 1.43e2.05). The
mortality rate ratio formenwas 1.06 (95% CI 1.02e1.10), and
was 1.21 (95% CI 1.14e1.27) in women (Fig. 2).Table 3 Standardised mortality rates and Poisson regression m
Ndths Personeyears
(million)
Morta
(stan
100 0
Year period
ICD-8 1968e1972 109 270 0.04
1973e1978 84 330 0.03
1979e1983 96 270 0.04
ICD-9 1984e1988 97 270 0.04
1989e1994 106 330 0.03
1995e2000 117 330 0.04
ICD-10 2001e2004 101 220 0.05
2005e2008 168 220 0.08
Sex
Male 591 110 0.05
Female 287 110 0.03
Age group
0e54 117 160 0.01
55e59 78 130 0.06
60e64 112 130 0.08
65e69 139 100 0.14
70e74 156 870 0.18
75e79 133 720 0.18
80e84 99 530 0.19
85þ 44 490 0.09
All the mortality rate ratios are mutually adjusted for all other variaSarcoidosis
Therewere3544 deaths fromSarcoidosis anda slight increase
in mortality rates throughout the study period, increasing
from 0.12 (95%CI 0.11e0.13) per 100 000 person years in the
1968e1972 calendar period to 0.22 (95% CI 0.20e0.24) per
100 000 person years. After controlling for the effects of sex
and age, we calculated that the overall year on year increase
in mortality was approximately 9% (rate ratio 1.09, 95% CI
1.07e1.10). Mortality was higher in females than males, and
highest in individuals aged 60e79 years (see Table 4).
There was evidence of a statistical interaction to suggest
that the increase in mortality rates over time were higher in
the older population (P < 0.001). For individuals aged 0e34
years the age group specific rate ratio was 0.95 (95%
CI 0.89e1.02). Individuals in the 40e44 age group had a rate
ratio of 1.07 (95% CI 1.01e1.14), in those aged 45e49 years it
was 1.01 (95%CI 0.95e1.07), for those aged50e54years itwas
1.03 (95% CI 0.98e1.09), for those aged 55e59 years it was
1.04 (95% CI 1.00e1.09) and for those aged 60e64 years the
rate ratiowas 1.02 (95%CI 0.98e1.06). Those in the 65e69 age
group had a rate ratio of 1.08 (95% confidence interval of
1.03e1.12), the 70e74 age group had a rate ratio of 1.16 (95%
confidence interval of 1.11e1.21), those in the 75e79 age
group had a rate ratio of 1.17 (95% confidence interval of
1.12e1.23) and those in the 80e84 age group had a rate ratio
of 1.43 (95% confidence interval of 1.33e1.55). The rate ratio
peaked in those aged 85 years and above with 1.52 (95%
confidence interval of 1.35e1.71) (Fig. 3).odelling of deaths from Extrinsic Allergic Alveoltis.
lity rate
dardised to 2008 pop per
00 (95% confidence interval))
Mutually adjusted
rate ratios
(95% confidence intervals)
(0.03e0.05) 1.00
(0.02e0.03) 0.64 (0.48e0.85)
(0.03e0.04) 0.88 (0.67e1.16)
(0.03e0.04) 0.89 (0.68e1.17)
(0.03e0.04) 0.81 (0.62e1.06)
(0.03e0.04) 0.89 (0.69e1.16)
(0.04e0.06) 1.16 (0.88e1.52)
(0.07e0.09) 1.93 (1.51e2.45)
p for trend <0.001
(0.05e0.06) 1.00
(0.02e0.03) 0.41 (0.36e0.48)
p value < 0.001
(0.01e0.01) 0.12 (0.09e0.16)
(0.05e0.07) 1.00
(0.07e0.10) 1.43 (1.07e1.91)
(0.12e0.16) 2.37 (1.80e3.13)
(0.15e0.21) 3.08 (2.35e4.05)
(0.16e0.22) 3.24 (2.45e4.29)
(0.15e0.23) 3.40 (2.52e4.57)
(0.07e0.12) 1.76 (1.21e2.55)
p for trend <0.001
bles in the table.
Figure 2 Estimated number of deaths from Extrinsic Allergic
Alveolitis, age standardised to the 2008 population of England
and Wales.
Table 4 Standardised mortality rates and Poisson regression modelling of deaths from Sarcoidosis.
Ndths Personeyears
(million)
Mortality rate (standardised to
2008 pop per 100 000 (95%
confidence interval))
Mutually adjusted rate ratios
(95% confidence intervals)
Calendar period
ICD-8 1968e1972 328 270 0.12 (0.11e0.13) 1.00
1973e1978 418 330 0.13 (0.12e0.14) 1.06 (0.92e1.23)
1979e1983 360 270 0.13 (0.12e0.15) 1.10 (0.95e1.27)
ICD-9 1984e1988 447 270 0.16 (0.15e0.18) 1.36 (1.18e1.57)
1989e1994 540 330 0.17 (0.15e0.18) 1.37 (1.20e1.57)
1995e2000 539 330 0.17 (0.15e0.18) 1.37 (1.19e1.57)
ICD-10 2001e2004 433 220 0.20 (0.18e0.22) 1.65 (1.43e1.90)
2005e2008 479 220 0.22 (0.20e0.24) 1.83 (1.59e2.10)
p for trend <0.001
Sex
Male 1569 110 0.14 (0.14e0.15) 1.00
Female 1975 110 0.17 (0.17e0.18) 1.14 (1.07e1.22)
p value <0.001
Age group (years)
0e34 168 980 0.02 (0.02e0.02) 0.17 (0.13e0.21)
35e39 167 160 0.10 (0.09e0.12) 1.00
40e44 223 170 0.13 (0.11e0.15) 1.26 (1.03e1.54)
45e49 255 160 0.16 (0.14e0.18) 1.57 (1.29e1.91)
50e54 334 140 0.24 (0.22e0.27) 2.36 (1.96e2.84)
55e59 406 130 0.31 (0.28e0.34) 2.99 (2.50e3.58)
60e64 460 130 0.35 (0.32e0.38) 3.36 (2.81e4.01)
65e69 472 100 0.47 (0.43e0.52) 4.58 (3.84e5.46)
70e74 444 870 0.51 (0.47e0.56) 4.93 (4.13e5.89)
75e79 346 720 0.48 (0.43e0.53) 4.61 (3.83e5.55)
80e84 186 530 0.35 (0.30e0.40) 3.34 (2.71e4.12)
85 and above 83 490 0.17 (0.14e0.21) 1.59 (1.22e2.07)
p for trend <0.001
All the mortality rate rations are mutually adjusted for all other variables in the table.
Figure 3 Estimated number of deaths from Sarcoidosis, age
standardised to the 2008 population of England and Wales.
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Using routinely available mortality data, we found that the
mortality fromAsbestosis has increased by ten-fold,mortality
from Sarcoidosis has almost doubled whilst mortality from
Extrinsic Allergic Alveolitis (EAA) has generally remained
stable over a forty year period, in England and Wales. We
found that death registrations were higher in men in Asbes-
tosis and EAA,whilst in Sarcoidosis itwas higher inwomen.We
also found that mortality rates were higher in the older age
groups for all three diseases. On the basis of our findings, we
would expect 108 deaths from Asbestosis, 48 deaths from EAA
and 132 deaths from Sarcoidosis each year in England and
Wales.
The main strength of our study is the large number of
registered deaths and the long period of time that this
information was obtained over. This meant that we were
able to stratify the results by age groups, sex and calendar
period and provide precise estimates of mortality rates
from each type of interstitial lung disease. Studies of this
magnitude are extremely difficult to conduct in a clinical
setting, due to the relatively small number of cases that
present each year to secondary or tertiary referral centres.
The main potential weakness of our study is the validity
of the diagnosis of Asbestosis, EAA and Sarcoidosis within
our dataset. Because we have used routinely available
mortality data, it is impossible to ascertain the diagnostic
criteria used for diagnosing the respective types of inter-
stitial lung disease. Although we have not formally vali-
dated the diagnoses of the above conditions in death
certificate registration, we are reassured by a previous
study which showed the diagnostic accuracy of death
certification of cryptogenic fibrosing alveolitis (CFA) to be
high.1 The same study showed that only 60% of individuals
with CFA had the disease recorded in their death certifi-
cate. If you take this to apply to all types of interstitial lung
disease, it is likely that our findings are an underestimation
of the true mortality rates of these diseases. It is also our
belief that it is unlikely for an individual to have a recording
for interstitial lung disease on their death certificate
without it being previously confirmed by secondary or
tertiary care, especially in cases of Asbestosis, an occupa-
tional lung disease where patients are able to claim
compensation.
Another potential weakness in our study is the possibility
of coding errors as three different International Classifica-
tion of Diseases (ICD) versions were used throughout the
study period. This is a possible explanation for the steep
decline innumber of deaths codedas being fromAsbestosis in
2007 and 2008. The mortality trend for Asbestosis from 1968
to 2006 showed a rapidly increasing number of deaths
recorded each year, and it is unlikely for there to be such
a sharp decline in number of deaths over such a short period
of time. There were also numerous ICD codes used when
collecting mortality data from Sarcoidosis. We used the ICD
codes to indicate underlying cause of death from all mani-
festations of Sarcoidosis (see Table 1), which raises the
possibility that our mortality rates are an overestimation of
mortality from pulmonary sarcoid. However, previous
research suggests that around 90% of cases with Sarcoidosis
havepulmonary involvement,4 and it is the commonest causeof death among this patient group. Furthermore, the
mortality rates for all three types of interstitial lung disease
are likely to be a conservative estimate of the total number
of deaths, as we have only collected data from death
certificate registration on the underlying cause of death and
not all causes of mortality recorded on a death certificate.
There is limited data on the trends in either incidence or
mortality from Asbestosis, EAA and Sarcoidosis and our find-
ings are similar to studies done previously. The Great Britain
Asbestosis survey among British asbestos workers reported
477 deaths from Asbestosis from 1971 to 2005.5 However, this
study was limited to workers with known Asbestosis exposure
and is probably an underestimation of the actual mortality
burden fromAsbestosis. The rise in Asbestosismortality in our
study mirrors the trends in mortality from mesothelioma
reported by Hodgson and colleagues, who predicted
a continuous rise in deaths from mesothelioma that is
expected to peak between 2011 and 2015.6 We would expect
the same trend to apply with Asbestosis, as both Asbestosis
and mesothelioma have a long latency periods between
exposure and manifestation of symptoms.
We have previously found that incidence rates of EAA in
primary care to be stable over a long period of time, with
an overall rate of 0.9 per 100 000 person years.7 This
complements our findings of a stable mortality rate
throughout our study period. Our findings of a slight
increase in mortality rates from Sarcoidosis is similar to
trends found in a study conducted in the United States,
which showed an annual increase of approximate 3% and
higher mortality rates in women compared to men.8
In summary, our findings suggest that Asbestosis,
Extrinsic Allergic Alveolitis and Sarcoidosis are becoming
important causes of respiratory mortality in the UK.
However, the true burden of disease among this group of
patients cannot be ascertained by mortality alone, as many
patients remain stable but significantly disabled for long
period of time. The significant morbidity associated with all
three disease groups is important when deciding on allo-
cation of health resources in the future and highlights the
need for better evidence based treatment options for these
conditions.Conflict of interest
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